PAGE 7 — MISDIAGNOSIS

Misdiagnosis: When the Wrong Diagnosis Leaves Families Unsafe

7.1 The Diagnostic Overlap Problem

The symptoms of quinoline-induced neurotoxicity and combat-related PTSD are clinically overlapping to the point of frequent indistinguishability on standard psychiatric assessment.

Both conditions can produce: hyperarousal and persistent sleep disturbance; nightmares and night terrors; irritability, anger dysregulation, and explosive rage; emotional numbing, avoidance, and relational withdrawal; concentration and memory difficulties; paranoid ideation in severe cases; dissociative episodes; and suicidal ideation.

This overlap is not coincidental. Mefloquine has been identified in the peer-reviewed literature as a significant potential confounder in the diagnosis and management of PTSD and related deployment-related neuropsychiatric disorders (Nevin and Ritchie, 2016). When a veteran presents with this symptom profile to a clinician trained in PTSD but untrained in quinoline neurotoxicity — which describes virtually every clinician in the current system — the diagnosis will almost inevitably be PTSD or a related psychiatric disorder.

The QVFA submission documents that affected veterans with chronic neuropsychiatric symptoms who seek help are almost universally diagnosed with PTSD without ever being referred to acquired brain injury specialists for proper screening, diagnosis, or treatment. Many have undergone years of treatment with medications including SSRIs and, in some cases, electroconvulsive therapy for what is characterised as treatment-resistant PTSD or depression — treatments calibrated to psychiatric illness, not acquired brain injury.

Evidential register: Symptom overlap: established (peer-reviewed literature, product data sheet) / Universal misdiagnosis of ADF veterans: documented (QVFA submission) — scale is advocacy-sourced and has not been independently verified / Individual treatment histories: documented in advocacy record.

7.2 What Happens When the Diagnosis Is Wrong

When quinoline neurotoxicity is misdiagnosed as PTSD, the consequences extend beyond the individual veteran. They reach directly into the household and affect the safety of the partner.

The treatment approach is calibrated to the wrong injury. SSRIs and trauma-focused psychotherapy address psychiatric illness and the neurological effects of psychological trauma. They do not address acquired brain injury of pharmacological origin. Ineffective treatment means the neurological substrate of dangerous behaviour — the limbic injury, the disinhibition, the paranoid ideation — remains unaddressed. The household remains unsafe.

Trauma-focused therapy may, in a neurologically compromised individual, amplify rather than reduce arousal, paranoia, and reactivity. Repeatedly engaging with combat memories and distressing content can increase the very responses that make the home dangerous.

The clinical frame of PTSD directs the veteran's attribution of distress toward the combat experience. In some cases this may intensify, rather than reduce, the sense of threat and betrayal that the paranoid symptom profile generates in domestic settings.

Family members are enrolled in support frameworks designed for trauma rather than brain injury. These frameworks do not provide the safety planning, neurological education, or practical supports appropriate to a household where someone has an acquired brain injury affecting impulse control and paranoid ideation.

Domestic violence services that encounter these families apply a perpetrator-accountability and trauma framework appropriate for most domestic violence presentations, but not calibrated to pharmacologically-induced disinhibition. This mismatch may lead to inadequate safety planning and outcomes that serve neither the veteran nor the partner.

Evidential register: Treatment mismatch consequences: plausible mechanism, consistent with clinical literature on ABI vs psychiatric treatment / Domestic violence service mismatch: structural analysis — stated as such.

7.3 The Perverse Incentive Structure

The DVA claims system contains a structural problem that actively reinforces misdiagnosis.

There is no Statement of Principles (SOP) for acquired brain injury (ABI) in the DVA entitlements framework, regardless of cause. A veteran correctly diagnosed with quinoline-induced ABI cannot make a successful DVA claim under the current system. However, a veteran misdiagnosed with PTSD or another psychiatric disorder can claim under existing SOPs for those conditions.

The system therefore financially incentivises the wrong diagnosis. It rewards the misidentification of a neurological injury as a psychiatric condition. It provides an entitlements pathway for the incorrect clinical picture and closes it off for the correct one.

The consequences for domestic safety are direct: a system that financially rewards the wrong diagnosis is a system that perpetuates the wrong treatment, indefinitely, for veterans and their families.

Evidential register: SOP structure and ABI gap: established (DVA entitlements framework documentation, QVFA submission) / Characterisation as a perverse incentive: analytical — stated as such.

7.4 What Has Changed Since the Royal Commission

The institutional position described above has been significantly but partially altered by recent events.

The Royal Commission into Defence and Veteran Suicide, whose Final Report was tabled in September 2024, devoted a dedicated chapter to mefloquine and tafenoquine and recommended that Defence and DVA establish a brain injury program for serving and ex-serving members exposed to these drugs, structured to assess and treat neurocognitive issues whatever their cause.

In December 2024, the Australian Government accepted or agreed in principle to 104 of the Commission's 122 recommendations. Work on the brain injury program is reported to be underway.

This represents genuine progress. The long-standing official position — that there was no established link between quinoline exposure and neurological injury — is no longer the government's stated position. A recognition framework for veterans, at least in principle, is being developed.

What remains unchanged:

The SOP gap for acquired brain injury has not been resolved. The brain injury program's scope, funding, and delivery have not yet been tested in practice. The program does not extend recognition or support to spouses or family members. Domestic violence services have received no training or guidance specific to quinoline-related neurotoxicity. The family law and criminal law systems operate without any framework for the neurological context of quinoline exposure.

The misdiagnosis problem and its downstream consequences for family safety remain active. They are not solved by a recommendation that has been accepted in principle.